Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
publishDate:"[2021 TO 2021]"
topic_facet:"Medical Condition: corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation MedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1Level: PTClassification code 10066262Term: Acute graft versus host disease in skinSystem Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1Level: PTClassification code 10066263Term: Acute graft versus host disease in liverSystem Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=publishDate%3A%22%5B2021+TO+2021%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+corticosteroid-refractory+acute+graft+vs.+host+disease+after+allogeneic+stem+cell+transplantation+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066260Term%3A+Acute+graft+versus+host+diseaseSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066262Term%3A+Acute+graft+versus+host+disease+in+skinSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066264Term%3A+Acute+graft+versus+host+disease+in+intestineSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066263Term%3A+Acute+graft+versus+host+disease+in+liverSystem+Organ+Class%3A+10021428+-+Immune+system+disorders%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=publishDate%3A%22%5B2021+TO+2021%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+corticosteroid-refractory+acute+graft+vs.+host+disease+after+allogeneic+stem+cell+transplantation+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066260Term%3A+Acute+graft+versus+host+diseaseSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066262Term%3A+Acute+graft+versus+host+disease+in+skinSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066264Term%3A+Acute+graft+versus+host+disease+in+intestineSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066263Term%3A+Acute+graft+versus+host+disease+in+liverSystem+Organ+Class%3A+10021428+-+Immune+system+disorders%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=publishDate%3A%22%5B2021+TO+2021%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+corticosteroid-refractory+acute+graft+vs.+host+disease+after+allogeneic+stem+cell+transplantation+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066260Term%3A+Acute+graft+versus+host+diseaseSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066262Term%3A+Acute+graft+versus+host+disease+in+skinSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066264Term%3A+Acute+graft+versus+host+disease+in+intestineSystem+Organ+Class%3A+10021428+-+Immune+system+disorders+MedDRA+version%3A+20.1Level%3A+PTClassification+code+10066263Term%3A+Acute+graft+versus+host+disease+in+liverSystem+Organ+Class%3A+10021428+-+Immune+system+disorders%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (22)
1
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
2
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
3
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
4
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
5
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
Safety and efficacy of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation : A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
3
Nächster »
[3]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Erscheinungsjahr: 2021-2021
Filter aufheben
Thema: Medical Condition: corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation MedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1Level: PTClassification code 10066262Term: Acute graft versus host disease in skinSystem Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1Level: PTClassification code 10066263Term: Acute graft versus host disease in liverSystem Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
22
Aufsätze
22
E-Artikel
22
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
22
610
Medical Condition: corticosteroid-refractory ac...
22
Phase: Phase 3
22
Study Type: Interventional
20
Recruitment Status: Not yet recruiting
2
Recruitment Status: Authorised-recruitment may ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2021-2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
22
Englisch
Haven't found what you're looking for?
Wird geladen...